Brilliant minds backing Solid IO’s mission

At Solid IO we are building a new functional approach to understanding tumor immune interactions and make better decisions in cancer treatments and drug development. As our work progresses, we are proud to introduce our newest advisors, a group of brilliant minds whose experience spans clinical diagnostics, pharma strategy, translational immuno-oncology, healthcare market dynamics and global commercialization. Their insight accelerates our progress and strengthens the foundation of what we are building, and we are inspired by the opportunity to work with them as we continue our mission to make powerful immuno-oncology treatments more accessible for patients around the world.

Amir Aref

Translational Immuno-Oncology and Ex Vivo Platforms
Dr Aref is a scientific leader with academic experience from the MIT, Harvard Medical School, Dana Farber Cancer Institute and Massachusetts General Hospital, where he has contributed to the development and validation of advanced non animal tumor microenvironment models. He has led translational programs involving more than 2,800 patient samples, and has played a key role in shaping several next generation ex vivo and human based model platform companies. With more than 200 peer reviewed publications and over 18,000 citations, he brings deep expertise in translating complex biology into impactful technologies.

Shannon Bennett

Regulatory Affairs and Clinical Laboratory
With almost three decades at Mayo Clinic, one of the largest US hospital systems, Shannon brings extensive experience in LDT development, internationally recognized laboratory standards and FDA regulatory pathways. This expertise is essential for building clinically and commercially viable diagnostics.

Elizabeth Jennings

Commercial Strategy and Global Market Access

Elizabeth has 15 years of experience supporting the international expansion of new healthcare technologies with a focus on adoption and reimbursement across the EU and US. She brings deep expertise in health economics and in navigating how innovations are evaluated by health systems, investors and public agencies. Having worked across 28 countries and contributed to studies on care delivery and economic value in oncology and diagnostics, she offers a broad and practical perspective on how emerging diagnostic platforms gain traction in global markets.

Carina Ruwolt

Ecosystem Strategy
Dr Ruwolt is the Director of Strategy at Bayer Pharmaceuticals and previously spent six years at The Boston Consulting Group working with clients across pharma, medtech, payers, and providers across Europe and the US. She brings a strategic understanding of how new technologies are evaluated and adopted across the healthcare ecosystem and how value is created for different stakeholders.

Daren Wilson

Global Pharma Strategy and Commercialization
Daren has led commercialization and clinical to commercial translation at Roche, Novartis and MSD. He brings a deep understanding of how pharma assesses, integrates and scales emerging technologies, offering valuable insight into strategic thinking around partnerships, validation and early market engagement.

A warm welcome!